Two Sigma Investments LP lessened its holdings in shares of Zafgen Inc (NASDAQ:ZFGN) by 49.6% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 223,368 shares of the biopharmaceutical company’s stock after selling 219,884 shares during the quarter. Two Sigma Investments LP owned about 0.60% of Zafgen worth $172,000 at the end of the most recent quarter.
A number of other hedge funds and other institutional investors have also bought and sold shares of the stock. Sphera Funds Management LTD. boosted its stake in Zafgen by 809.4% in the 1st quarter. Sphera Funds Management LTD. now owns 3,161,562 shares of the biopharmaceutical company’s stock worth $2,434,000 after purchasing an additional 2,813,892 shares during the period. Point72 Asset Management L.P. purchased a new position in shares of Zafgen in the fourth quarter worth $230,000. Renaissance Technologies LLC grew its stake in Zafgen by 8.9% during the fourth quarter. Renaissance Technologies LLC now owns 2,385,677 shares of the biopharmaceutical company’s stock valued at $2,648,000 after acquiring an additional 195,056 shares in the last quarter. Finally, Jane Street Group LLC bought a new stake in Zafgen in the 4th quarter valued at $67,000. 70.43% of the stock is currently owned by institutional investors.
NASDAQ ZFGN opened at $13.29 on Wednesday. The stock has a 50 day moving average price of $7.03 and a 200-day moving average price of $2.51. Zafgen Inc has a one year low of $0.62 and a one year high of $2.76. The company has a debt-to-equity ratio of 0.26, a quick ratio of 6.56 and a current ratio of 6.56. The company has a market capitalization of $497.98 million, a P/E ratio of -13.84 and a beta of 0.27.
Separately, ValuEngine upgraded Zafgen from a “hold” rating to a “buy” rating in a research report on Thursday, April 2nd. Three investment analysts have rated the stock with a hold rating and two have given a buy rating to the company. The company currently has an average rating of “Hold” and a consensus target price of $0.77.
Zafgen Company Profile
Zafgen, Inc, a clinical-stage biopharmaceutical company, develops therapies for patients suffering from metabolic diseases comprising type 2 diabetes, Prader-Willi syndrome (PWS), and other metabolically related disorders. The company's lead product candidate is ZGN-1061, a fumagillin-class methionine aminopeptidase 2 (MetAP2) inhibitor administered by subcutaneous injection, which is in Phase 2 clinical trial and profiled for its utility in the treatment of type 2 diabetes and other related metabolic disorders.
Featured Article: Why Invest in Dividend Kings
Receive News & Ratings for Zafgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zafgen and related companies with MarketBeat.com's FREE daily email newsletter.